osteoarthritis

This article was originally published on The Fresh Toast and appears here with permission. Although owners are always discouraged from using cannabis products formulated for humans on their pets, there is a growing variety of hemp derived products that may help relieve joint pain. You see them in...

Providing patients with chronic back pain and osteoarthritis (OA) access to medical cannabis can reduce or even eliminate the use of opioids for pain management, according to two studies presented at the 2022 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS). The studies, led by...

Psychedelics and cannabinoid neuroscience company Enveric Biosciences (NASDAQ: ENVB) announced the development of two new molecular conjugates for osteoarthritis and other pain indications, which mix CBD with Celecoxib, a generic drug commonly prescribed for ...

Osteoarthritis (OA) can result in significant pain, often requiring pain management with opioids, which can be addictive. According to a study performed by researchers at Thomas Jefferson University and the Rothman Orthopaedic Institute in Philadelphia, medical cannabis has the potential to be...

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) reported results following toxicology and pharmacokinetic study of Epoladerm to manage pain associated with osteoarthritis of the knee. Charles River Laboratories International Inc (NYSE: CRL), CRO engaged by Virpax, completed the study...

Ampio Pharmaceuticals Inc (NYSE: AMPE) has reported top-line results from the AP-013 Phase 3 trial evaluating the Company's intra-articular (IA) injection of Ampion in adults with pain due to severe osteoarthritis of the knee (OAK).  Related Link: Ampio's Phase 2 Study Of...

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) Phase 2 study of Resiniferatoxin (RTX) for moderate-to-severe osteoarthritis of the knee pain (OAK). The Phase 2 trial, a multi-center, double-blind, placebo- and active-controlled study, will assess the efficacy...

Can-Fite BioPharma Ltd (NYSE: CANF) has signed a development and commercialization agreement with France-based veterinary biotech company, Vetbiolix, to develop Piclidenoson to treat osteoarthritis in companion animals. Vetbiolix will have the exclusive right to Piclidenoson in...

Galapagos NV (NASDAQ: GLPG) is chopping its pipeline to conserve cash while its business development team pursues a mission to find a “transformative” deal for the company. The company is ditching its Idiopathic pulmonary fibrosis (IPF) molecule ’1205 while...

An expert panel of the U.S. Food and Drug Administration has rejected Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company’s (NYSE: LLY) application to approve their experimental drug for the treatment of osteoarthritis pain, citing safety risks and an inadequate plan to manage them....

Ahead of an advisory committee meeting scheduled for later this week, the FDA released its in-depth review of Pfizer Inc (NYSE: PFE) and Eli Lilly And Co’s (NYSE: LLY) tanezumab, an anti-NGF osteoarthritis drug. What Happened: Potential FDA approval for...

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) — which specializes in developing transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders — were trading in the green Thursday. The stock gained ground after the International Intellectual Property...

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares were rallying Monday following the announcement of positive trial results for its osteoarthritis knee pain treatment candidate. In pre-market trading, the stock was trading up 3.7 percent to $5.60. Shares were down 0.46 percent at $5.38...

Despite confirming third-quarter catalysts and progress throughout its development pipeline, Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)’s first-quarter financial report didn’t impress investors. The company conceded an 8.3-percent stock decline Tuesday even as it boasts a 22-percent...